Ipca Laboratories Ltd

Ipca Laboratories Ltd

₹ 1,574 -0.06%
21 Nov - close price
About

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)

Key Points

Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]

Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]

  • Market Cap 39,957 Cr.
  • Current Price 1,574
  • High / Low 1,709 / 1,041
  • Stock P/E 64.1
  • Book Value 264
  • Dividend Yield 0.25 %
  • ROCE 12.8 %
  • ROE 9.35 %
  • Face Value 1.00

Pros

  • Company has been maintaining a healthy dividend payout of 17.2%

Cons

  • Stock is trading at 5.96 times its book value
  • Company has a low return on equity of 11.4% over last 3 years.
  • Debtor days have increased from 65.3 to 80.3 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
1,544 1,430 1,289 1,586 1,601 1,546 1,512 1,585 2,034 2,053 2,033 2,093 2,355
1,184 1,123 1,070 1,317 1,341 1,330 1,331 1,278 1,673 1,722 1,711 1,700 1,913
Operating Profit 360 308 219 269 260 216 181 308 361 331 322 393 441
OPM % 23% 22% 17% 17% 16% 14% 12% 19% 18% 16% 16% 19% 19%
18 12 15 22 36 31 36 45 -1 91 -118 21 26
Interest 1 1 3 7 9 11 18 31 44 33 29 24 23
Depreciation 57 59 61 62 64 67 70 69 90 100 98 99 100
Profit before tax 320 260 170 223 223 169 129 252 225 289 77 290 345
Tax % 21% 22% 17% 33% 35% 32% 37% 34% 39% 23% 96% 31% 29%
252 198 132 145 146 110 78 164 136 221 1 199 246
EPS in Rs 9.86 7.74 5.13 5.64 5.67 4.25 3.02 6.42 5.72 7.09 2.35 7.58 9.05
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
2,813 3,282 3,144 2,867 3,156 3,258 3,746 4,619 5,395 5,797 6,204 7,662 8,533
2,248 2,539 2,604 2,573 2,705 2,803 3,051 3,715 3,843 4,472 5,272 6,338 7,046
Operating Profit 565 743 541 294 451 455 695 904 1,552 1,325 932 1,324 1,487
OPM % 20% 23% 17% 10% 14% 14% 19% 20% 29% 23% 15% 17% 17%
13 21 32 21 11 41 56 65 59 54 123 17 20
Interest 36 30 32 35 27 28 22 20 12 11 48 141 109
Depreciation 87 103 180 163 173 178 182 210 209 232 262 357 397
Profit before tax 454 631 361 117 262 291 546 739 1,389 1,136 745 843 1,001
Tax % 29% 24% 28% 18% 26% 18% 19% 18% 17% 20% 34% 37%
324 479 254 93 195 239 442 604 1,141 890 479 523 667
EPS in Rs 12.82 18.96 10.07 3.69 7.71 9.49 17.60 23.99 44.94 34.85 18.58 21.57 26.07
Dividend Payout % 16% 13% 5% 0% 6% 5% 9% 10% 9% 11% 22% 19%
Compounded Sales Growth
10 Years: 9%
5 Years: 15%
3 Years: 12%
TTM: 28%
Compounded Profit Growth
10 Years: 2%
5 Years: 5%
3 Years: -21%
TTM: 23%
Stock Price CAGR
10 Years: 17%
5 Years: 23%
3 Years: 16%
1 Year: 44%
Return on Equity
10 Years: 13%
5 Years: 15%
3 Years: 11%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 25 25 25 25 25 25 25 25 25 25 25 25 25
Reserves 1,529 1,934 2,183 2,234 2,430 2,663 3,097 3,590 4,676 5,439 5,817 6,307 6,675
617 603 935 867 716 628 465 501 265 807 1,481 1,438 1,202
526 648 669 765 788 799 961 1,142 1,099 1,349 1,300 3,326 3,521
Total Liabilities 2,697 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,622 8,623 11,097 11,424
1,104 1,354 1,800 2,014 1,983 1,953 1,940 2,059 2,072 2,402 2,751 4,554 4,523
CWIP 129 165 267 129 95 73 66 133 235 306 140 343 485
Investments 9 9 16 26 136 87 120 310 505 989 626 862 944
1,455 1,683 1,729 1,723 1,746 2,003 2,422 2,756 3,254 3,924 5,105 5,339 5,472
Total Assets 2,697 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,622 8,623 11,097 11,424

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
389 522 468 709 282 341 501 570 1,090 856 806 945
-260 -369 -689 -218 -149 -135 -165 -509 -521 -851 -725 -1,215
-83 -136 251 -462 -159 -130 -183 -137 -306 427 507 -553
Net Cash Flow 46 18 29 29 -26 75 153 -76 264 432 588 -823

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 54 50 41 57 58 67 66 71 55 57 58 80
Inventory Days 247 272 293 289 290 286 316 294 337 337 276 350
Days Payable 89 110 97 145 130 137 154 135 140 101 83 110
Cash Conversion Cycle 212 213 237 200 218 216 228 229 251 293 251 321
Working Capital Days 112 98 106 84 94 107 109 113 119 127 119 150
ROCE % 24% 28% 14% 5% 9% 10% 16% 19% 31% 20% 11% 13%

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.30% 46.30% 46.30%
12.34% 11.02% 10.61% 10.57% 10.46% 10.58% 10.05% 9.86% 10.27% 10.51% 10.85% 10.83%
30.02% 32.70% 33.49% 33.46% 33.71% 33.74% 34.86% 34.72% 34.19% 34.05% 33.46% 33.90%
0.24% 0.24% 0.24% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32%
11.11% 9.75% 9.37% 9.34% 9.22% 9.06% 8.46% 8.80% 8.93% 8.82% 9.07% 8.64%
No. of Shareholders 1,06,7791,15,3351,10,8181,11,0431,08,1771,10,29699,88995,93082,80981,16584,75382,975

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls